{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:43:59Z","timestamp":1764603839402,"version":"3.44.0"},"reference-count":42,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To conduct network meta\u2010analysis (NMA) of clinical efficacy and safety of single\u2010dose antiviral drugs, grouped by dosage, in treatment of influenza. Systematic retrievals were conducted in databases, including Pubmed, Embase, Web of Science, the Cochrane Register of Clinical Trials and from the website ClinicalTrials.gov, for clinical trials recorded between the interception of the databases and March 31, 2021. Randomized controlled trials (RCTs) of influenza treatment in which single\u2010dose antiviral drugs were administered were selected according to preset inclusion and exclusion criteria by two researchers who screened the literature independently from each other. The quality of the included studies was assessed using the Cochrane bias risk assessment tool. Software such as Stata 16.0 and Review Manager 5.3 was adopted for statistical analysis. Pairwise meta\u2010analysis and NMA were carried out under the random\u2010effects model. For both binary and continuous variables, odds ratio (OR), mean difference (MD) and their 95% confidence intervals (CI) were used to rank treatment efficiencies and analyze the differences. A total of 12 RCTs involving 7296 participants were included in the analysis. According to the NMA results, peramivir 300\u2009mg (MD\u2009=\u2009\u221217.68, 95% CI: [\u221234.05, \u22121.32]), peramivir 600\u2009mg (MD\u2009=\u2009\u221216.15, 95% CI: [\u221229.35, \u22122.95]), baloxavir (MD\u2009=\u2009\u221214.67, 95% CI: [\u221226.75, \u22122.58]) and laninamivir 40\u2009mg (MD\u2009=\u2009\u221212.42, 95% CI: [\u221222.53, \u22122.31]) remarkably outperformed laninamivir 20\u2009mg in time to alleviation of symptoms (TTAS). However, no intervention statistically outperform others in antipyretic time, virus titer variations against the baseline 24 and 48\u2009h after medication and adverse events (AEs). The efficacy rankings were: peramivir 300\u2009mg (the surface under the cumulative ranking curve [SUCRA]\u2009=\u200980.3%)\u2009&gt;\u2009peramivir 600\u2009mg (SUCRA\u2009=\u200976.2%)\u2009&gt;\u2009baloxavir (SUCRA\u2009=\u200968.4%)\u2009&gt;\u2009laninamivir 40\u2009mg (SUCRA\u2009=\u200955.0%)\u2009&gt;\u2009laninamivir 20\u2009mg (SUCRA\u2009=\u200916.6%) for TTAS; baloxavir (SUCRA\u2009=\u200976.3%)\u2009&gt;\u2009peramivir 600\u2009mg (SUCRA\u2009=\u200967.8%)\u2009&gt;\u2009laninamivir 40\u2009mg (SUCRA\u2009=\u200947.2%)\u2009&gt;\u2009laninamivir 20\u2009mg (SUCRA\u2009=\u200940.0%) for antipyretic time; baloxavir (SUCRA\u2009=\u200996.7%)\u2009&gt;\u2009peramivir 300\u2009mg (SUCRA\u2009=\u200964.5%)\u2009\u2248\u2009peramivir 600\u2009mg (SUCRA\u2009=\u200963.2%), baloxavir (SUCRA\u2009=\u200993.2%)\u2009&gt;\u2009peramivir 600\u2009mg (SUCRA\u2009=\u200964.0%)\u2009\u2248\u2009peramivir 300\u2009mg (SUCRA\u2009=\u200955.0%), for virus titer variations against the baseline 24 and 48\u2009h after medication, respectively; and baloxavir (SUCRA\u2009=\u200983.4%)\u2009&gt;\u2009peramivir 300\u2009mg (SUCRA\u2009=\u200971.4%)\u2009&gt;\u2009laninamivir 20\u2009mg (SUCRA\u2009=\u200962.4%)\u2009&gt;\u2009peramivir 600\u2009mg (SUCRA\u2009=\u200956.2%)\u2009&gt;\u2009laninamivir 40\u2009mg (SUCRA\u2009=\u200936.8%) for adverse events. Among the single\u2010dose anti\u2010influenza virus drugs compared, peramivir is superior to baloxavir and laninamivir in TTAS, whereas baloxavir has the best efficacy in antipyretic time, virus titer variations against the baseline 24 and 48\u2009h after medication and AEs. This study has been registered in the International Prospective Register of Systematic Reviews (PROSPERO), with a registration number of CRD42021238220.<\/jats:p>","DOI":"10.1002\/jmv.27729","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T05:43:37Z","timestamp":1647927817000},"page":"3270-3302","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of single\u2010dose antiviral drugs for influenza treatment: A systematic review and network meta\u2010analysis"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9537-4133","authenticated-orcid":false,"given":"Yonghong","family":"Zhao","sequence":"first","affiliation":[{"name":"The Second Hospital of HeBei Medical University Shijiazhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3520-2609","authenticated-orcid":false,"given":"Guangliang","family":"Huang","sequence":"additional","affiliation":[{"name":"The Second Hospital of HeBei Medical University Shijiazhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0228-9317","authenticated-orcid":false,"given":"Wenjuan","family":"He","sequence":"additional","affiliation":[{"name":"The Second Hospital of HeBei Medical University Shijiazhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1831-1715","authenticated-orcid":false,"given":"Qian","family":"Sun","sequence":"additional","affiliation":[{"name":"The Second Hospital of HeBei Medical University Shijiazhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4350-2022","authenticated-orcid":false,"given":"Xiaojuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Second Hospital of HeBei Medical University Shijiazhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-9886","authenticated-orcid":false,"given":"Dan","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Hospital of HeBei Medical University Shijiazhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0858-4229","authenticated-orcid":false,"given":"Huichao","family":"Wang","sequence":"additional","affiliation":[{"name":"The Second Hospital of HeBei Medical University Shijiazhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0949-0005","authenticated-orcid":false,"given":"Wenyan","family":"Cui","sequence":"additional","affiliation":[{"name":"The Second Hospital of HeBei Medical University Shijiazhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2809-2491","authenticated-orcid":false,"given":"Xiuju","family":"Liu","sequence":"additional","affiliation":[{"name":"The Second Hospital of HeBei Medical University Shijiazhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.10.008"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30129-0"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33293-2"},{"issue":"18","key":"e_1_2_11_5_1","first-page":"75","article-title":"Strengthen pharmaceutical care to improve medication compliance of patients","volume":"25","author":"Cai F","year":"2017","journal-title":"J Trad Chin Med Manage"},{"issue":"11","key":"e_1_2_11_6_1","first-page":"1070","article-title":"Study on the factors influencing the compliance of statins in the patients with hyperlipidemia and the risk prediction","volume":"18","author":"Chen J","year":"2021","journal-title":"Chin J Pharmacovig"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0543"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz284"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-5151(03)00091-4"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-017-4199-3"},{"key":"e_1_2_11_11_1","unstructured":"HigginsJ GreenS.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2013."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2015.09.002"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1037"},{"issue":"11","key":"e_1_2_11_15_1","first-page":"1352","article-title":"A suite of network commands in stata for network meta\u2010analysis","volume":"15","author":"Zhang TS","year":"2015","journal-title":"Chin J Evid\u2010Based Med"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"issue":"7","key":"e_1_2_11_17_1","first-page":"884","article-title":"Differentiation and handling of homogeneity in network meta\u2010analysis","volume":"14","author":"Zhang C","year":"2014","journal-title":"Chin J Evid\u2010Based Med"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500402"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0373-0"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716197"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002747"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30004-9"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12788"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx129"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01755-09"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1086\/656802"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00360-11"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-012-0460-1"},{"key":"e_1_2_11_31_1","unstructured":"BioCryst Pharmaceuticals. A phase II multicenter mandomized placebo\u2010controlled study to evaluate the efficacy and safety of intramuscular peramivir 600 mg in subjects with uncomplicated acute influenza.http:\/\/ClinicalTrials.gov\/show\/NCT00705406"},{"key":"e_1_2_11_32_1","unstructured":"Johns Hopkins University. ED influenza therapeutic pilot study: oseltamivir vs. peramivir.http:\/\/ClinicalTrials.gov\/show\/NCT02609399"},{"key":"e_1_2_11_33_1","unstructured":"BioCryst Pharmaceuticals. Safety PK and effectiveness of IV peramivir versus oseltamivir in pediatric subjects with uncomplicated influenza.http:\/\/ClinicalTrials.gov\/show\/NCT02369159"},{"issue":"8","key":"e_1_2_11_34_1","first-page":"899","article-title":"Progress of clinical research of peramivir in the treatment of influenza","volume":"26","author":"Liu XJ","year":"2017","journal-title":"Chin J New Drugs"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00474-10"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70138-3"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.22146"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27890-4"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051653"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit034"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12216"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1584505"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1839400"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.27729","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.27729","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.27729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T10:43:05Z","timestamp":1758019385000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.27729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1002\/jmv.27729"],"URL":"https:\/\/doi.org\/10.1002\/jmv.27729","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"type":"print","value":"0146-6615"},{"type":"electronic","value":"1096-9071"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"assertion":[{"value":"2021-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}